Monday, January 12, 2015

Celgene Upbeat on Revlimid Growth

Celgene warned that foreign-currency impacts will partly dent sales gains tied to its blockbuster blood cancer drug Revlimid.



from WSJ.com: US Business http://ift.tt/1BcqZeS

via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)